Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Platinum-resistant Ovarian Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 250Nivolumab 144Cisplatin 138Cyclophosphamide 137Paclitaxel 116Carboplatin 112Gemcitabine 100Radiotherapy 86Dexamethasone 84Docetaxel 79Ipilimumab 70atezolizumab 68Doxorubicin 63Fluorouracil 60Blood Specimen Collection 60Bevacizumab 59Etoposide 55fludarabine 54Rituximab 54Oxaliplatin 52Prednisone 51Lenalidomide 51Surveys and Questionnaires 50Cetuximab 47Standard of Care 46Capecitabine 46Radiosurgery 45Magnetic Resonance Spectroscopy 45lenvatinib 43durvalumab 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × afuresertib × 1 year × Clear all
NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Laekna Limited

Phase 1/2 Completed
22 enrolled
GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT04374630 2025-09-10

PROFECTA-II

Laekna Limited

Phase 2 Completed
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡